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ABSTRACT
Introduction: Many patients with ulcerative colitis
(UC) present with acute exacerbations needing hospital
admission. Treatment includes intravenous steroids but
up to 40% of patients do not respond and require
emergency colectomy. Mortality following emergency
colectomy has fallen, but 10% of patients still die
within 3 months of surgery. Infliximab and ciclosporin,
both immunosuppressive drugs, offer hope for
treating steroid-resistant UC as there is evidence of
their short-term effectiveness. As there is little long-
term evidence, this pragmatic randomised trial, known
as Comparison Of iNfliximab and ciclosporin in
STeroid Resistant Ulcerative Colitis: a Trial
(CONSTRUCT), aims to compare the clinical and
cost-effectiveness of infliximab and ciclosporin for
steroid-resistant UC.
Methods and analysis: Between May 2010 and
February 2013, 52 UK centres recruited 270 patients
admitted with acute severe UC who failed to respond
to intravenous steroids but did not need surgery. We
allocated them at random in equal proportions
between infliximab and ciclosporin.The primary
clinical outcome measure is quality-adjusted survival,
that is survival weighted by Crohn’s and Colitis
Questionnaire (CCQ) participants’ scores, analysed by
Cox regression. Secondary outcome measures
include: the CCQ—an extension of the validated but
community-focused UK Inflammatory Bowel Disease
Questionnaire (IBDQ) to include patients with acute
severe colitis and stoma; two general quality of life
measures—EQ-5D and SF-12; mortality; survival
weighted by EQ-5D; emergency and planned
colectomies; readmissions; incidence of adverse
events including malignancies, serious infections and
renal disorders; disease activity; National Health
Service (NHS) costs and patient-borne costs.
Interviews investigate participants’ views on therapies
for acute severe UC and healthcare professionals’
views on the two drugs and their administration.
Ethics and dissemination: The Research Ethics
Committee for Wales has given ethical approval (Ref.
08/MRE09/42); each participating Trust or Health
Board has given NHS Reseach & Development
approval. We plan to present trial findings at
international and national conferences and publish in
high-impact peer-reviewed journals.
Trial registration number: ISRCTN: 22663589;
EudraCT number: 2008-001968-36
INTRODUCTION
This paper summarises the current approved
protocol in use at 68 participating centres
across the UK.
Background
Ulcerative colitis (UC) is a chronic debilitat-
ing disease that affects about 150 000 people
in the UK.1 2 Many patients with UC
present with acute severe colitis requiring
inpatient admission. Treatment includes
intravenous steroids but about 40% of
patients are resistant to steroids. In the past
when no other treatments were available,
emergency colectomy was the only option.
Strengths and limitations of this study
▪ A multicentre, UK-wide, pragmatic randomised
trial of 270 participants recruited at 52 sites.
▪ Use of mixed methods to compare clinical and
cost-effectiveness and assess professional and
patient views.
▪ Formal follow-up using designed data collection
for up to 3.5 years after randomisation and
routine data for 10 years.
▪ Study limited to the UK.
▪ Rigorous blinding limited to main study team
including analysts.
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Although mortality following emergency colectomy has
fallen over time, 10% of patients die within 3 months of
surgery.3
Inﬂiximab and ciclosporin are immunosuppressive
drugs that offer hope for the treatment of
steroid-resistant UC. There is evidence that they are
both effective in the short term,4 particularly among
patients who respond partially to steroid treatment.
Several studies support the use of inﬂiximab in
patients with moderate or severe UC,4–7 especially
steroid-resistant patients who do not tolerate ciclos-
porin.6 A systematic review and meta-analysis of 34 inﬂix-
imab studies found an average short-term response and
remission of 68% and 40%, respectively, and an average
long-term response and remission of 53% and 39%,
respectively.7 Two large randomised controlled trials
(RCTs) also found highly signiﬁcant improvements in
total Inﬂammatory Bowel Disease Questionnaire (IBDQ)
scores and Short Form-36 physical and mental compo-
nent scores for inﬂiximab patients at 8 weeks when com-
pared with placebo.8 Current UK National Institute for
Health and Care Excellence (NICE) guidelines allow
the use of inﬂiximab only when ciclosporin is contrain-
dicated or as part of a research study.9
Several studies support the use of ciclosporin as a safe
and effective treatment for steroid-resistant UC,10–12
although it has side effects including dose-related tox-
icity11 13 14 and long-term failure.11–13 15 A systematic
review and meta-analysis of 16 ciclosporin studies
reported a mean short-term response rate of 73% but
poor long-term response rates11; one study reported that
65% of patients relapsed after 1 year, 90% relapsed after
3 years13 and 58% needed colectomy after 7 years.15
Another review of 32 studies reported a 51% short-term
success rate.16 However, the relevant Cochrane review
concluded that there was limited evidence that ciclos-
porin was more effective than standard treatment for
severe UC and that long-term beneﬁts were unclear.17 It
also advocated research into the long-term effects of
ciclosporin on quality of life and cost-effectiveness.
A recent meta-analysis of 361 patients in six retrospective
cohort studies concluded that inﬂiximab and ciclosporin
are comparable when used as rescue therapy in acute
severe steroid-resistant UC. However, the outcome mea-
sures were limited to colectomy rates, adverse drug reac-
tions and postoperative complications over 12 months.18 A
recent meta-analysis of 38 patients with steroid-resistant
UC showed that the 20 on ciclosporin had a higher colec-
tomy rate, more steroid dependency and more adverse
events (AEs) than the 18 on inﬂiximab.19
Against this background of studies that compared
these two drugs only indirectly, la Groupe d’Etude
Thérapeutique des Affections Inﬂammatoires Digestives
(GETAID) recently reported on the trial ‘CYcloSporine
versus InFliximab (CYSIF)’,20 the ﬁrst head-to-head com-
parison of these two drugs. CYSIF found no signiﬁcant
differences in ‘treatment failure’ within 98 days, deﬁned
as any of: (1) no clinical response after 7 days; (2) no
remission without steroids after 98 days; (3) relapse
between 7 and 98 days; (4) serious AE leading to treat-
ment interruption; (5) colectomy or (6) death. However,
CYSIF recruited only 110 patients, followed them for
only 98 days, reported no data on quality of life, and col-
lected no data on costs.
In summary, inﬂiximab and ciclosporin are often
effective in the short term, but there is little long-term
evidence, especially about comparative clinical and cost-
effectiveness. The Evidence Review Group Report
commissioned by NICE21 concluded: ‘The results con-
sistently indicate that the move from standard care to
ciclosporin is highly cost-effective. Thus the policy ques-
tion is clear: should we make a subsequent move from
ciclosporin to inﬂiximab.’ Hence we have designed
Comparison Of iNﬂiximab and ciclosporin in STeroid
Resistant Ulcerative Colitis: a Trial (CONSTRUCT) to
achieve a rigorous and comprehensive comparison of
these costly therapies.
In response to this debate, the CONSTRUCT team
has recently extended the measurement of quality of life
and costs in four ways:
▸ By extending data collection for all trial participants,
whenever recruited, until early 2014;
▸ By adding questionnaires at 18, 30 and 36 months;
▸ By adding four questionnaires following colectomy
and any ensuing corrective surgery;
▸ By planning to use survival analysis, statistical missing
value imputation and economic modelling to impute
quality of life and costs for all participants who gener-
ate data after randomisation.
Aim and objectives
The aim of this trial is to compare the clinical and cost-
effectiveness of inﬂiximab and ciclosporin for patients
with steroid-resistant UC over a period of up to 3.5 years.
Speciﬁc objectives are to:
1. Compare health-related quality of life between the
two treatments (inﬂiximab and ciclosporin).
2. Compare mortality, disease activity and morbidity
between treatments.
3. Compare (emergency) colectomy rates between
treatments.
4. Compare cost-effectiveness of the two treatments in
terms of cost per quality-adjusted life-year.
5. Extend this comparison by modelling lifetime costs
and effects.
6. Investigate the views of patients about these
treatments.
7. Investigate the views of healthcare professionals
about the drugs, and their administration and ease of
handling.
METHODS
Trial design
CONSTRUCT is a two-arm, pragmatic randomised trial
(ﬁgure 1). Participating patients and their doctors knew
which of the two drugs they were receiving. As the two
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modes of administration are different, any other
approach would have been difﬁcult. Fortunately this
pragmatic approach enables us to compare the clinical
and cost-effectiveness of the drugs in normal clinical
practice, whereas the more explanatory double-blind
placebo controlled trial would have compared the efﬁ-
cacy of the drugs under stricter, less realistic,
conditions.22
To this design we added a comprehensive cohort to
help recruit patients into a complex trial. Following
explanation we invited inpatients with known or sus-
pected colitis to join the cohort as soon as possible after
admission. We told them that if they had UC and did
not respond to intravenous steroids, they might need
other drug treatment; and, if they were suitable, we
would invite them to have further treatment as part of a
clinical trial. To increase the chance of recruiting them,
and ensure the quality of their data, we collected their
baseline data as soon as possible after they had given
consent. Although our primary aim in recruiting this
cohort was to enhance recruitment to the trial, it has
potential to enhance future study of UC, notably
through anonymised linkage to routine data.23
From May 2010 to the end of February 2013 we
recruited from the cohort to the trial those participants
diagnosed with UC (assessed by Truelove and Witts cri-
teria,24 a Mayo score of at least 2 on endoscopy, or clin-
ical judgement) who failed to respond to a course of up
to about 5 days of intravenous steroids but did not need
immediate surgery. After the clinical team had con-
ﬁrmed steroid resistance, and full oral and written
explanation, we invited participants who fulﬁlled the
trial inclusion criteria to consent to randomisation to
either inﬂiximab or ciclosporin. A placebo control
group would have been unethical, as these patients are
severely ill and need treatment, as the NICE Evidence
Review Group recognised.21
Sample size and power
The current design of CONSTRUCT requires a combin-
ation of survival analysis and statistical imputation to get
full value from the resulting dataset. As these techniques
are difﬁcult to incorporate into power calculations, we
present a simpler calculation based on t tests of mean
Crohn’s and Colitis Questionnaire (CCQ) scores at
12 months. For CONSTRUCT to detect an effect size of
0.35 in these scores (ie, a difference between inﬂiximab
and ciclosporin groups of at least 0.35 of the population
SE) with 80% power when using a 5% signiﬁcance level
requires that we analyse at least 250 of the 270 partici-
pants recruited to the trial. Although more than 10% of
CONSTRUCT participants are likely to drop out over
the follow-up period of at least 12 months, all analyses
will exploit the techniques of statistical imputation used
successfully by the Cancer of the Oesophagous or
Gastricus: New Assessment of the Technology of
Endosonography (COGNATE)25 and Folate
Augmentation of Treatment—Evaluation of Depression
(FolATED)26 trials to maintain the effective sample size
at 250. Our initial, more conservative power calculation
had proposed: to recruit 480 participants; not to impute
missing data statistically; therefore to allow for 25% loss
to follow-up; and thus to yield 80% power to detect a
slightly smaller effect size of 0.30 in CCQ scores. We
amended our target to 270 participants once the difﬁ-
culty of identifying patients with acute steroid-resistant
UC became clear early in recruitment.
Routine data
Designed research data collection will continue until
April 2014. We shall supplement the designed data col-
lected from cohort participants by operational data from
their electronic records, routine data on National
Figure 1 Comparison Of iNfliximab and ciclosporin in
STeroid Resistant Ulcerative Colitis: a Trial (CONSTRUCT)
flowchart.
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Health Service (NHS) resource use from Hospital
Episode Statistics (HES) and mortality data from the
Ofﬁce for National Statistics (ONS).
We plan to continue follow-up for up to 10 years
through record linkage of routine mortality, inpatient
and primary care data using the existing facilities of the
Medical Research Council (MRC)-funded Centre for
Improving Population Health through E-health
Research (CIPHER) in the College of Medicine of
Swansea University. We hope to monitor all participants’
long-term outcomes, including mortality, emergency col-
ectomy, elective colectomy and major morbidity includ-
ing hospitalisation and surgery, and thus most of their
NHS costs. Thus we aim to achieve both long-term
follow-up for trial participants and to create a larger
electronic comprehensive cohort of patients with inﬂam-
matory bowel disease (IBD).
Trial management
The management structure includes: Trial Steering
Committee (TSC) which provides oversight of the trial
and meets at six monthly intervals, Data Monitoring and
Ethics Committee (DMEC) which monitors trial data in
accordance with an agreed charter and reports to the
TSC, and Trial Management Group (TMG) comprising
academics, health professionals, researchers and repre-
sentatives of service users and the Swansea Clinical Trials
Unit—the West Wales Organisation for Rigorous Trials
in Health (WWORTH). The TMG undertakes general
management of the trial, meets every month and
reports to the TSC. In accordance with the relevant
WWORTH standard operating procedure,27 we include
service users as active contributors at all stages of this
study. They attend the TSC, DMEC and TMG where
they contribute to the research process and provide valu-
able insights into UC.
Setting and site selection
We invited consultant gastroenterologists to express
interest in taking part in the study via the British Society
of Gastroenterology by completing a feasibility question-
naire. We considered sites which had treated four or
more patients with steroid-resistant UC in the previous
12 months to be eligible and invited them to seek local
approval. As a result we are undertaking the study in 68
NHS Health Boards or Trusts, including large teaching
and district general hospitals in England, Scotland and
Wales.
Informed consent
Patients who were eligible for the cohort received
Cohort Participant Information Leaﬂets and oral explan-
ation about the cohort from consultant gastroenterolo-
gists or research professionals (usually research nurses);
they gave written consent by signing and dating a
Cohort Consent Form. Cohort participants who became
eligible for the trial received Trial Participant
Information Leaﬂets and oral explanation about the
trial; they gave written consent by signing and dating a
Trial Consent Form. For cohort and trial, those taking
consent countersigned and dated the form to conﬁrm
that the participant had fully understood the nature of
the study and had had opportunity to ask questions;
they also put a copy of that consent in the medical
record, and gave another copy to the participant.
Research professionals could take consent to the cohort
if authorised to do so on the Site Delegation Log following
appropriate training including Good Clinical Practice
(GCP). Although they could also explain the trial to
cohort participants, responsibility for countersigning lay
with the site principal investigator (PI) or another doctor
with delegated authority on the Site Delegation Log.
Withdrawal
The process of consenting participants stressed that they
could withdraw from cohort or trial whenever they wished
without giving a reason and without affecting their care in
any way. We documented reasons given where available. We
encouraged participants who withdrew from completing
questionnaires to continue other types of follow-up. We
encouraged site staff to trace participants lost to follow-up
and document the reasons for their loss when possible.
Clinical judgements that participants had not
responded to treatment with inﬂiximab or ciclosporin
usually led to surgical intervention; however, those parti-
cipants remained in the trial, especially for analysis by
treatment allocated, unless they chose to withdraw.
Between randomisation and the end of the trial, there
were many decisions made by clinicians to discontinue
or change allocated treatments; again this did not consti-
tute withdrawal from this pragmatic trial.
Trial inclusion criteria
Patients admitted as emergency admissions with severe
colitis who fail to respond to up to about 5 days of intra-
venous hydrocortisone therapy, who also have either:
A. Histological diagnosis of UC in this episode;
B. Histological diagnosis of indeterminate colitis in this
episode, where clinical judgement (based on macro-
scopic appearance, disease distribution or a history)
suggests a diagnosis of UC rather than Crohn’s
disease;
C. Symptoms typical of UC while histology awaited;
D. History of UC (previously conﬁrmed histologically).
We withdrew from treatment participants with B, C or
D who were later found not to have UC but kept them
in the trial and followed them up in the usual way.
Trial exclusion criteria
1. Age under 18 years on admission
2. Pre-randomisation histological diagnosis inconsistent
with UC (cf inclusion criterion ‘B’)
3. Enteric infection conﬁrmed before randomisation
by stool microscopy, culture or histology (includes
Campylobacter, Clostridium difﬁcile,
Cytomegalovirus, Salmonella and Shigella)
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4. Vulnerable patient
5. Unable to consent
6. Positive pregnancy test or currently lactating
7. Woman of child-bearing potential but not prepared
to use contraception during, and for 6 months after,
treatment with inﬂiximab in accordance with the
Summary of Product Characteristics
8. Current malignancy, excluding basal cell carcinoma
9. Serious co-morbidity, including:
i. Immunodeﬁciency
ii. Myocardial infarction (within last month)
iii. Moderate or severe heart failure (New York
Heart Association (NYHA) class III or IV)
iv. Acute stroke (within last month)
v. Respiratory failure
vi. Renal failure
vii. Hepatic failure
viii. Active or suspected active tuberculosis
ix. Other severe infections such as sepsis, abscesses
and opportunistic infections
x. History of hypersensitivity to inﬂiximab, ciclos-
porin or polyethoxylated oils (Sandimmun
Concentrate for intravenous infusion)
10. Concomitant use of tacrolimus or rosuvastatin
11. English not good in absence of local translation
services
12. Clinical need to undergo emergency colectomy
without further medical treatment
13. Currently taking part in another clinical trial
14. Treatment with either inﬂiximab or ciclosporin in
the 3 months before admission
15. Contraindication(s) to treatment with inﬂiximab or
ciclosporin
Randomisation
We allocated all patients who completed baseline obser-
vations, met the inclusion criteria but none of the exclu-
sion criteria, and gave informed consent—at random
between inﬂiximab or ciclosporin. We used a web-based
password-protected site with a dynamic algorithm to
protect against subversion while ensuring that each arm
of the RCT was balanced by centre.28
For validation, the website requested additional
information.
A. Participant’s study number, and month and year of
birth.
B. Name of the person who was requesting randomisa-
tion (limited to those trained and authorised).
C. Has consent been given?
D. Does the patient meet the inclusion criteria?
E. Does the patient have none of the exclusion criteria?
F. Has the baseline questionnaire been completed?
If the responses to the last four questions were ‘Yes’,
the patient was randomised.
The research staff requesting randomisation received
the name of the drug to be allocated to the participant
and immediate conﬁrmation of the study number and
drug by email. The outcomes of randomisation are
recorded on the randomisation database, in the trial
master ﬁle at Swansea University, at the study site in partici-
pants’ records, and in the remotely hosted data repository.
The drugs were held in hospital pharmacies at trial
sites. When a participant was randomised, the research
staff faxed the relevant pharmacy a copy of the conﬁrm-
ation of participant study number and drug. The drug
was labelled with the EudraCT number, sponsor, partici-
pant’s study number, name and address of supplier, ‘For
Clinical Trial Use Only’ and the dose directions.
Blinding
As this was an open trial, there was no need for proce-
dures to enable study sites to reveal random allocations.
Nevertheless we shall keep the CI, statistician and other
staff responsible for analysis and reporting blind to treat-
ment allocated and received until they complete
primary analysis to the satisfaction of TSC and DMEC.
Interventions
Participants randomised to inﬂiximab received it as
remicade in 5 mg/kg intravenous infusions over 2 h—at
baseline and 2 and 6 weeks after the ﬁrst infusion, in
accordance with local prescribing guidelines.
Participants randomised to ciclosporin received it as
sandimmun by continuous infusion of 2 mg/kg/day.
Sites were advised to change the infusion every 6 h using
non-polyvinyl chloride bags and administration sets but,
given the pragmatic nature of the trial, could follow
local practice. Intravenous treatment continued for up
to 7 days if successful. Sites switched participants
responding to ciclosporin to twice-daily oral doses deli-
vering 5.5 mg/kg/day, and adjusted doses to achieve
trough ciclosporin concentration of 100–200 ng/mL.
They measured whole-blood ciclosporin levels according
to local practice, ideally 48 h after oral therapy and then
every 2 weeks. After 12 weeks treatment was at the discre-
tion of the participant’s consultant. We asked centres to
consult the online Summary of Product Characteristics
for remicade or sandimmun and oral ciclosporin at the
time of ﬁrst prescription.
For both treatments we gave centres discretion to start
azathioprine or 6-mercaptopurine at therapeutic doses
in week 4. We asked them to eliminate steroids by week
12 in patients who remained well but to reinstate them
in patients who became symptomatic. We also advised
centres to give septrin as prophylaxis against Pneumocystis
jiroveci (carinii) pneumonia in both groups.
Outcome measures
Until April 2014, that is between 1 and 3.5 years from
randomisation, we shall continue to measure:
1. Primary outcome measure of quality-adjusted survival,
weighted by scores on the disease-speciﬁc CCQ which
we are validating concurrently. The CCQ expands the
validated UK IBDQ29 to cover acute illness and the
period after colectomy.
Seagrove AC, Alam MF, Alrubaiy L, et al. BMJ Open 2014;4:e005091. doi:10.1136/bmjopen-2014-005091 5
Open Access
Quality of life:
2. Disease-speciﬁc quality of life, measured by the CCQ.
3. Generic quality of life, measured by SF-1230 and
EQ-5D31 questionnaires.
Main clinical outcomes:
4. Mortality.
5. Colectomies, both emergency and planned.
6. Readmissions, including those for non-UC-speciﬁc
causes.
7. Adverse events, subdivided into suspected unexpected
serious adverse reactions (SUSARs), serious adverse reac-
tions (SARs), serious AEs (SAEs), adverse reactions
(ARs) and AE, including all relevant events in 4–6 above.
Incidence of rarer clinical outcomes:
8. Malignancies, subdivided between colorectal, other
gastrointestinal and other.
9. Serious infections, including bacterial infections, pneu-
monia and abscesses.
10. Renal disorders.
11. Other new symptoms, especially attributable to
treatment.
Disease activity:
12. Criteria proposed by Truelove and Witts24: full blood
count, inﬂammatory markers and albumin at base-
line and 3, 6, 12, 18, 24, 30 and 36 months.
Economic outcomes:
13. NHS costs, measured by a healthcare resource use
questionnaire and hospital activity data.
14. Patient-borne costs, including number of days off work
and travel costs to healthcare.
Qualitative outcomes:
15. Patient views of both drugs and their implications.
16. Professional views about the drugs, their administra-
tion and ease of handling.
Safety monitoring and reporting
Responsibility for ensuring GCP adherence and report-
ing AEs in accordance with the clinical trial regulations
is the delegated responsibility of the PI and the research
team at each site, documented in a clinical trial agree-
ment in place with each site.
All AEs are recorded and assessed by the PI or other
designated person, using an AE Screening Form to judge
the seriousness, causality and expectedness of the event. If
uncertain the PI will summarise the event and refer the
decision to the CI. Serious AEs, including SUSARS, are
reported to the DMEC and an annual safety report, includ-
ing serious adverse reactions, is submitted to the Medicines
and Healthcare products Regulatory Agency (MHRA) and
Research Ethics Committee (REC) for Wales.
To help identify AEs, trial participants are given a
membership card showing their study ID. They are
asked to show this whenever they are seen by a doctor
who is not part of the team treating them for UC.
Data collection
We ask all trial participants to complete questionnaires
(including CCQ, SF-12 and EQ-5D) at baseline and 3, 6
and 12 months; and to complete them at 18, 24, 30 and
36 months if they reach these timepoints before April
2014.
In addition, we also ask all trial participants who
undergo a colectomy or subsequent corrective surgery
to complete the postcolectomy version of CCQ on dis-
charge following surgery, and at 4, 8 and 12 weeks after
discharge; we have elaborated the original trial design in
these ways to strengthen our estimation of
quality-adjusted survival, the primary outcome measure
for CONSTRUCT.
We collect baseline data for all patients at recruitment
to cohort, including:
Sociodemographic data
A. Age, sex, ethnic group and truncated postcodes,
which will be used to generate measures of social
deprivation (Index of Multiple Deprivation for
England, Welsh Index of Multiple Deprivation for
Wales, Carstairs’ Deprivation Scores for Scotland,
Northern Ireland Multiple Deprivation Measure
scores, and Townsend scores for all four countries).
Administrative data
B. Admission details
Clinical data
C. Disease history including presenting symptom, dur-
ation of disease since ﬁrst diagnosis, previous
medical and surgical treatments received, and details
of any previous biological, concomitant or steroid
therapies.
D. Comorbidities in particular cardiorespiratory, liver and
renal disease, diabetes and hypertension.
E. UC symptoms and signs including duration of symp-
toms in current episode, stool frequency, blood pres-
sure, pulse and temperature.
F. Treatment including type, dose and duration of steroid
therapy.
G. Pathology results including full blood count, erythro-
cyte sedimentation rate, C reactive protein,
γ-glutamyltransferase, glomerular ﬁltration rate,
albumin, liver function tests, urea, creatinine, electro-
lytes, total cholesterol and total bilirubin.
H. Extent of disease and colonic area affected (Montreal
classiﬁcation of IBD32).
I. Histopathology results including stool culture results and
histological diagnosis.
J. Family history of IBD.
K. General: height, weight and smoking status.
Quality of life
L. Quality of life (QoL) measures. The three QoL measures
are administered as one questionnaire as soon as
feasible following consent to the cohort; completion
of these questionnaires by trial participants must
precede randomisation to inﬂiximab or ciclosporin.
Economic evaluation
Cost-utility analysis will use the EQ-5D to estimate
quality-adjusted life years (QALYs) and estimated costs
from an NHS perspective. Patient-level data on resource
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use in hospital over the 3.5 years of the study is monitored
using GeneCIS and routinely collected data, supplemen-
ted where necessary by scrutiny of hospital medical
records. These include drugs, drug-related complications,
surgery, inpatient stay (in intensive care unit (ICU), high
dependency unit (HDU) or ward) and outpatient clinic
attendances. NHS resource use outside hospital, including
all contacts with health professionals in primary care and
the community, is estimated by the CONSTRUCTresource
use questionnaire, which is registered on the Database of
Instruments for Resource Use Measurement (DIRUM).33
We shall use current UK national prices where available
from published sources34 to value these costs; or, if not,
from the ﬁnance departments of participating sites.
Patient-borne costs are estimated by additional questions
at baseline, 3, 6 and 12 months, and potentially at 18, 24,
30 and 36 months, but will be reported separately from
the cost-utilty analysis.
Qualitative study
We interview participants by telephone to understand
their experiences and perceptions of treatment with
inﬂiximab or ciclosporin and other therapies for acute
severe UC. We invited all participants to show their will-
ingness to be interviewed on the trial consent form. We
used purposive quota sampling to identify 12 consenters
from each arm of the trial. This yielded a wide represen-
tation of therapy, age and sex of patients from a range
of centres. We interview them twice—at about 3 and
12 months after they receive treatment.
First interviews follow a structured format to ensure con-
sistency of data collection. The interviews investigate
patients’ priorities for their health and well-being, ease of
taking the drugs, side effects and response to treatment.
Follow-up interviews use a similar schedule but include
additional questions to explore what has happened to par-
ticipants following treatment, including changes over time
in their opinions of the treatment, their interactions with
healthcare professionals, and their health.
We also interview healthcare professionals, by tele-
phone or face-to-face, to understand their views about
the two drugs, their administration and ease of hand-
ling. We have recruited 15 doctors and 9 nurses, strati-
ﬁed by number of patients recruited by their sites.
These interviews address the ease of handling a range of
drugs for UC, aspects of drug provision that might inﬂu-
ence professional preference for one drug over another,
and impressions of other professional contributions to
treatment and care. This is particularly relevant if inter-
viewing consultant and nurse at the same site. This will
enable us to explore different professions’ ways of
working, in particular in treating and administering
drugs for UC, and thus professional interaction and psy-
chological development.
Data management and record keeping
All data acquisition, storage and transmission comply
with the Data Protection Act. The study uses the
portfolio of standard operating procedures developed
and maintained by the Swansea Clinical Trials Unit,
WWORTH, and trains staff accordingly, especially in
ensuring conﬁdentiality.
We use our own securely hosted, generic clinical infor-
mation system (GeneCIS) to support data handling and
record keeping. Data are held in a remote, profession-
ally managed repository and accessed over a virtual
private network via the secure NHS N3 network. The
system also supports data validation and facilitates
quality assurance, and is backed up comprehensively
every working day. We ask all patients to consent to data
capture using this system, and to linkage of their elec-
tronically held routine data. Other data sources include
participants’ medical records, pathology systems and
routine data from HES, mortality data from ONS, and
primary care systems. Participating sites have access only
to identiﬁable data for those participants under their
care, and cannot view any other records.
Aggregated data for analysis by the staff engaged in
quantitative reporting are extracted in pseudonymised
form. They do not have access to identiﬁable data and
remain blind to treatment allocated and received until
primary analysis is complete. In contrast qualitative
researchers have access to identiﬁable data—non-clinical
but not clinical. They audiotape and transcribe their
qualitative data, and store them securely, identifying
them only by the participant’s trial number. The Trial
Data Manager (TDM) is responsible for maintaining
data quality, reporting on that to both TMG and DMEC,
and supplying the DMEC with unblinded data in
response to formal requests. Hence the TDM has access
to all data, and will not contribute to analysis.
Analysis
Missing data
General principles
We shall adopt a consistent approach to missing data
relating to effectiveness and cost-effectiveness except
where individual outcome measures require variation in
that approach. We shall exclude participants without any
follow-up data. For each variable, we shall summarise the
frequency of missing data, which affects effective sample
size and hence statistical power. If there is reason to
suspect that data are not missing completely at random
(MCAR), the trial statistician and chief investigator will
discuss the ﬁndings. If not, we shall use appropriate
imputation methods to ameliorate the problem of
missing data.35
Internal imputation within a questionnaire at specific data
collection point
None of the questionnaires has an ofﬁcial algorithm for
imputing individual missing answers; fortunately most
measures with such algorithms use poor imputation
methods. Because all baseline QoL scores and most
follow-up scores originate from clinics with nurse assist-
ance if required, there should be few patients with many
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responses missing. Some of these will have personal
reasons for partial non-completion, so it is unlikely that
we accurately can impute their answers—conditionally
missing at random (MAR).
Nevertheless, to reduce missing data and make good
use of available information, we shall impute missing
responses within the three QoL measures. If the inci-
dence of missing data is low, we shall make single use of
the expectation maximisation (EM) version of the SPSS
Missing Value Analysis module. We shall then impute
the corresponding scale scores from the relevant instruc-
tions for that scale. If the incidence of missing data is
high, we shall consider using multiple imputation
methods.
External imputation of quality of life scores
If participants are dead at an interview point, we shall
set their EQ-5D scores to 0; to avoid introducing outliers,
we shall set their other QoL scores to the minimum
value observed for that measure in their treatment
group.
Otherwise, we shall impute missing summary scale
and subscale scores by appropriate regression models
from all available values of that score at other data
points and the allocated treatment group. We shall con-
sider including extra predictors such as age, gender and
whether currently hospitalised, but as they will usually
be covariates in the main analysis, they may play only a
limited role in predicting missing values.
Statistical analysis
This will address the ﬁrst three objectives. Reﬂecting the
pragmatic nature of the trial design, the primary analysis
will be ‘by treatment allocated’, also known as ‘by inten-
tion to treat’. The primary outcome measure will be
Quality-Adjusted Survival weighted by scores on the
disease-speciﬁc CCQ. Important predictors that may
affect QoL during follow-up, hence considered as factors
or covariates in general linear models (GLM), include:
A. Data collected at baseline during assessment for eligi-
bility for RCT including the sociodemographic vari-
ables age, sex, ethnic group, social deprivation
(derived from truncated post-codes) and other base-
line information collected for the cohort
investigation.
B. Data collected after randomisation such as concomi-
tant medical therapy, continuing steroid treatment,
and azathioprine or other immunosuppressive
therapy.
Study centre and the baseline value of the relevant
outcome measure will always be included in models.
Otherwise, if any potential factor or covariate has an F
value of less than 1 (and so increases SEs of estimates) it
will be removed from the model and the data reana-
lysed. Rare categories in some factors (such as ethnic
group) may need to be combined; if so, the categories
to be combined will be assessed before examining out-
comes, taking account only of observed numbers in
each category and the coherence of the new groupings.
Age will be treated as a covariate or factor (dichoto-
mised at the observed median) depending on goodness
of ﬁt. The treatment by centre interaction will be tested
by an F test.
Multiple observations of QoL measures (EQ-5D, SF-12
and CCQ) at different time points will be analysed using
the ‘area under the curve’ (AUC). This provides a link
with the economic analysis via QALYs, and gives a prac-
tical answer relevant to the objectives of the trial. QoL
observations will also be analysed as ‘repeated measures’
to test whether ﬁndings are sensitive to the choice of
AUC as main criterion.
The AUC and GLM analyses will be supplemented by
descriptive univariate comparisons of the mean QoL in
the two groups at each time point. Events such as mor-
tality and colectomy will be compared descriptively by
cross-tabulating the numbers and proportions in each
treatment group, with a CI for the relative risk of the
event occurring differentially in the two groups. Where
data are available on time to these events, an appropri-
ate survival analysis, based on Cox’s proportional hazard
approach36 will investigate differences by adjusting for
the same potential factors and covariates.
Residual diagnostics will be used where analyses assume
normality; if the distributions of residuals are markedly
non-normal, data transformation or bootstrapping will be
considered. Residual analysis will be used to identify out-
liers; these outliers will be excluded and the data reana-
lysed. Outcome descriptions, summaries and comparisons
will be expressed in accordance with appropriate
CONSORT guidelines (http://www.consort-statement.
org), including estimates with 95% CIs to summarise two-
tailed tests at the 5% signiﬁcance level.
Health economics analysis
This addresses the fourth and ﬁfth objectives, and com-
prises cost-utility analyses from an NHS perspective—
within trial and in the long term.
Within trial cost-utility analysis
The main effectiveness measure in this analysis will esti-
mate QALYs from EQ-5D scores at baseline and 3, 6, 12,
18, 24, 30 and 36 months for patients who reach these
time points in the trial. Costs will be valued using appro-
priate local and UK national prices where available, and
from published sources.34 Speciﬁcally the cost of hospi-
talisation (excluding those for surgical interventions)
will be calculated as the number of inpatient days in
each setting (ICU, HDU or ward) and relevant daily
unit costs. Costs of surgical procedures will be based on
the type of surgery multiplied by the most appropriate
health-related group reference cost. Drugs will be valued
using prices in the British National Formulary.
Mean differential costs between the two treatment
groups will be estimated. Since cost data are often
skewed, non-parametric bootstrapping will generate 95%
CIs around point estimates.
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If one treatment is dominant (lower cost, greater
effect) then that treatment is unambiguously more cost-
effective. If not, results will be reported as an incremen-
tal cost-effectiveness ratio (ICER) showing the extra cost
of producing one extra QALY. To decide whether the
treatment which is clinically more effective offers good
value for money, the ICER will be assessed against a
range of monetary thresholds representing the
maximum the NHS is prepared to pay for an extra
QALY (currently £20 000–£30 000). Treatment is
deemed cost-effective if the ICER falls below the
threshold.37
Inevitably there is uncertainty around estimated costs
and effects of medical interventions. Bootstrapping38
and Monte Carlo simulation techniques will be used for
trial analyses and modelling studies respectively to gen-
erate the sampling distribution of the mean costs and
effects, quantifying this uncertainty. Cost-effectiveness
acceptability curves (CEACs) will estimate CIs for the
ICERs.
Long-term cost-utility analysis
An existing decision-analytical model simulates the pro-
gression of hypothetical cohorts of patients with UC
receiving the two treatment strategies and tracks
lifetime-associated costs and QALYs.39 We shall populate
this model with data from our trial and thus enhance
the decision-tree model used for the ﬁrst 12 months. We
shall adapt the ensuing Markov model to extrapolate
beyond the main period of follow-up and estimate long-
term costs and QALYs. Since long-term efﬁcacy of inﬂixi-
mab in UC is unknown, the model considers a 10-year
time horizon to explore uncertainty in long-term out-
comes. We shall estimate the probability of surgery from
trial data for the period until 3 years and thus adjust the
life expectancy predicted by the Markov model. Costs
and QALYs will be discounted at 3.5% per annum.
The surgery rates used in the model will be based on
data from the trial over 36 months. The relationship
between transition probabilities and time will be estab-
lished from trial data using survival analysis. A paramet-
ric Weibull model will be employed to model these data
and convert event rates into probabilities. A probabilistic
sensitivity analysis40 with 10 000 simulations using
Bayesian Markov Chain Monte Carlo (MCMC) methods
will address the common problem of parameter uncer-
tainty in economic models.
Qualitative analysis
This addresses the last two objectives. We shall investi-
gate patients’ priorities for their health and well-being,
their experiences since treatment and their changing
opinions of treatment. In parallel we shall explore
healthcare professional views of the administration of
inﬂiximab and ciclosporin and the choice between
them.
Telephone interviews with participants, both patients
and professionals, will be recorded and transcribed.
Transcripts will undergo rigorous analysis by standard
thematic analysis based on the interview schedule and
by schematic analysis of whole-page summations of tran-
scripts.41 Thematic analysis is in keeping with a struc-
tured approach to data collection, whereby coding is
used as the “method for conceptualising research data
and classifying it into meaningful and relevant categor-
ies for participants in the study.”42
Three researchers will individually code transcripts
from ﬁrst-round interviews with patients as they are com-
pleted. When they have coded four interviews each, the
researchers will work together to agree a coding struc-
ture and develop an analysis framework. The same ana-
lysis framework will be followed with all transcripts and
data will be prepared for coding, including reading of
all transcripts and familiarisation with data. The same
process will be followed for the second-round interviews.
Three transcripts (one from a participant given inﬂixi-
mab, one given ciclosporin and one given ciclosporin
followed by surgery) will also be taken forward to group
analysis sessions for two reasons: to enhance the analysis
framework by verifying if aspects are cogent and agreed
by a wider group of analysts, and to give those analysing
other study datasets an insight into the lives of people
suffering from UC. Members of the study team will read
the three transcripts and write three one-page overviews
of the main features to tell the story of each participant’s
health and illness. There will then be a group discussion
session to see if there is consensus and if the analysis
framework is working. This iterative procedure ensures
the validity of the analysis framework and its use.
Once agreement is reached and code saturation is
achieved across transcripts, the remaining transcripts will
be coded by two of the three original qualitative
researchers using the adopted analysis framework. The
analysis of the professional interviews will broadly follow
the same structure.
Further analyses
No interim or subgroup analyses of trial outcomes are
planned. We do plan to triangulate ﬁndings from differ-
ent components of the study using the MATRICS
approach.43
We hope to follow participants annually for up to
10 years by questionnaire and record linkage of routine
data; the data thus obtained will identify future patterns
of costs and effects following the treatment received by
participants in the trial.
DISSEMINATION
Research governance
The study has EudraCT Number (2008-001968-36) and
clinical trial authorisation from the MHRA. It conforms
with the Research Governance Frameworks for
England,44 Scotland45 and Wales46; the principles of
GCP outlined by the International Conference on
Harmonisation (http://www.ich.org/); the EU directive
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2001/20/EC47; and the Medicines for Human Use
(Clinical Trials) Regulations 2004.48
Data sharing
Whilst funded by the NIHR HTA programme, we shall
adhere to the MRC-Wellcome Trust data sharing policy
and will make data arising from the project available to
the scientiﬁc community with as few restrictions as feas-
ible. We will retain exclusive use of data throughout the
project. Following completion of the project, we shall
deposit extensive anonymised data from this project at
the University of Essex data archive. We shall encourage
data sharing, especially through the Essex data archive.
Publication
In accordance with good practice we have registered
CONSTRUCT in a public registry at http://www.
controlled-trials.com/isrctn with ISRCTN 22663589. We
shall present study ﬁndings at national and international
conferences and publish as widely as we can in peer-
reviewed journals using the CONSORT guidelines.49 We
hope to recognise everyone who has worked on the trial.
DISCUSSION
We undertook a feasibility study to reﬁne patient path-
ways, and the CCQ and economic health resource-use
questionnaires. We then conducted a prepilot study to
test the recruitment process up to randomisation and
ensure that the main components of this trial worked
together. Thereafter we used the resulting cohort of
some 40 patients to test aspects of study design beyond
initial recruitment. Following the prepilot, we piloted
the use of the GeneCIS online data collection system,
patient recruitment, randomisation and primary data
collection. Each centre was asked to recruit and success-
fully randomise one participant. This was followed by a
meeting of investigators to learn from the pilot. As the
pilot uncovered no major problems, we have included
cohort and trial participants recruited during the pilot
period within the main study.
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